RT Journal Article SR Electronic T1 Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) JF bioRxiv FD Cold Spring Harbor Laboratory SP 2021.08.06.455494 DO 10.1101/2021.08.06.455494 A1 Lo, Michael K. A1 Shrivastava-Ranjan, Punya A1 Chatterjee, Payel A1 Flint, Mike A1 Beadle, James R. A1 Valiaeva, Nadejda A1 Schooley, Robert T. A1 Hostetler, Karl Y. A1 Montgomery, Joel M. A1 Spiropoulou, Christina YR 2021 UL http://biorxiv.org/content/early/2021/08/10/2021.08.06.455494.abstract AB The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.Competing Interest StatementThe authors have declared no competing interest.